ISH news • August 2022

View this email in your browser

August 2022

Each month the members of the Scientific and Education Committee of the International Society of Hematology (ISH) write this newsletter for our subscribers featuring relevant news in Global Hematology.
In this issue we highlight some important results coming from studies presented in Vienna during the EHA meeting and also from ASCO in Chicago.

Myeloma renaissance continues: more on CARTs and bispecifics

The advances in myeloma therapy continue. In EHA meeting results from a study developed in China using CAR-T cells against the BCMA antigen are very promising. Patients with RR multiple myeloma (n=79) were treated with BCMA-directed CAR-T therapy. The overall response was 94.9%, complete remission was 70%. Moreover, MRD negativity probability at one year was at an impressive 88.7%. Considering the very high-risk population included in the study these results are relevant and bring fresh air to this area of malignant hematology. In comparison, the new bispecific antibody teclistamab (CD3 anti BCMA) was used in RR MM patients, results were presented at ASCO 68% patients obtained n ORR and 39% CR or better. Responses were also durable. There will be more options for RR MM patients in the near future, but the cost will be, as always, a barrier for countries with low and middle incomes.

New JAK inhibitors in myelofibrosis

Momelotinib is a new drug. It is a JAK1/JAK2 inhibitor with the capacity to improve anemia in some patients with myelofibrosis. In the MOMENTUM trial this inhibitor was compared with danazol in patients with intermediate and high-risk patients with anemia and symptoms. Momelotinib bested danazol in these settings as presented in the ASCO meeting However, the cost issue will be important. Danazol is an effective old drug and has a low cost. Hard to beat in that sense.



The International Society of Hematology (ISH) will return to in-person meetings this year on October 6-8 along with the Spanish Society of Hematology (Sociedad Española de Hematología y Hemoterapia:  SEHH). After interruptions derived from the COVID 19 pandemic, we are back on our feet and will celebrate our 38th World ISH Congress. Our Spanish friends and colleagues have chosen the splendid city of Barcelona as the venue of the joint meeting, and we are confident that this will be an unforgettable hematology world congress. A solid and state of the art academic content will be presented.
Please save the date and be ready for this outstanding combined meeting. It will be a pleasure seeing you in Barcelona in October!
Keep safe,
David Gómez-Almaguer MD
ISH Chair of Council


Second generation FLT3 inhibitors improve upon 7+3

The potent FLT3-ITD oral inhibitor quizartinib seem to be effective among with FLT3-ITD positive AML. The study presented at EHA showed that this compound in combination with standard induction chemotherapy and as a single agent for up to 36 months doubles median overall survival (31.9 months) in AML patients without severe toxicity. Is this the new standard of care for this kind of AML patients? How will this drug come into play with midostaurin the first FLT3 inhibitor? We will like to see confirmatory data and compare between generations.


The 38th World Congress of the International Society of Hematology will be taking place during the annual Spanish hematology meeting from the Sociedad Española de Hematología y Hemoterapia in the beautiful city of Barcelona, October 6-8, 2022. The meeting will be hybrid taking place both in person and virtually. We’ll keep you posted regarding registration dates, abstract deadlines, and all meeting details soon. 



Become an ISH Delegate! Join the International Society of Hematology and connect with other professionals from all around the world who are interested in all areas of research, education, and healthcare policy.

Benefits of including an ISH member include

  • Opportunity to collaborate in ISH Committees
  • Submit and sponsor abstracts to the ISH World Congress
  • Reduced registration fee for the ISH Congress and meetings
  • Reduced author publishing fees for HEMATOLOGY journal

Want to contribute to the newsletter? Write to us



Journal ISH

Hematology is the official journal of the ISH published online by Taylor Francis.  It is an international open access journal publishing original research and reviews in the field of general hematology, including oncology, pathology, biology, clinical research, and epidemiology.
Hematology aims to bridge the interests and practice of both those carrying out laboratory work and those whose main inclination is patient care.  ISH members have a reduced author publishing fee to Hematology.

Copyright © 2022 Hematology Service. Centro Universitario Contra el Cancer., All rights reserved.
You are receiving this email because you subscribed on our website.

Our mailing address is:
Hematology Service. Centro Universitario Contra el Cancer.
Hospital Universitario "Dr. José E. González" UANL
Madero y Gonzalitos. Mitras Centro
Monterrey, NL 64460

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

This website is only for professional-level audience and health professionals
LookUs & Online Makale